Company intelligence / Profile preview

Alpha-5 Integrin

Ownership: Private
Development stage: Other

Overview

Alpha-5 Integrin was a privately held preclinical-stage biotechnology company developing a potentially first-in-class monoclonal antibody targeting alpha-5 integrin for amyotrophic lateral sclerosis and other neuroinflammatory disorders; the program had shown reproducible significant improvements in behavior and survival in the SOD1 mouse model of ALS and had not yet entered clinical trials at the time of its acquisition by Pasithea Therapeutics in June 2022.[1]

Therapeutic areas: Neurology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Alpha-5 Integrin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-5 Integrin.

Explore the full profile